Cymabay Therapeutics CEO Sujal Shah's 2019 pay jumps 32% to $2.6M
Cymabay Therapeutics reports 2019 executive compensation
By ExecPay News
Published: May 15, 2020
Cymabay Therapeutics reported fiscal year 2019 executive compensation information on May 15, 2020.
In 2019, five executives at Cymabay Therapeutics received on average a compensation package of $1.8M, a 1% decrease compared to previous year.
Average pay of disclosed executives at Cymabay Therapeutics
Sujal Shah, Chief Executive Officer, received $2.6M in total, which increased by 32% compared to 2018. 74% of Shah's compensation, or $1.9M, was in option awards. Shah also received $153K in non-equity incentive plan, $510K in salary, as well as $4.3K in other compensation.
Janet Dorling, Former Chief Commercial Officer, received a compensation package of $2M. 64% of the compensation package, or $1.3M, was in option awards.
Pol Boudes, Chief Medical Officer, earned $1.7M in 2019, a 8% increase compared to previous year.
Charles A. McWherter, Chief Scientific Officer, received $1.5M in 2019, which decreases by 16% compared to 2018.
Klara Dickinson, Chief Regulatory and Compliance Officer, earned $1.2M in 2019.
Related executives
Sujal Shah
Cymabay Therapeutics
Chief Executive Officer
Janet Dorling
Cymabay Therapeutics
Former Chief Commercial Officer
Pol Boudes
Cymabay Therapeutics
Chief Medical Officer
Charles McWherter
Cymabay Therapeutics
President of R&D
Klara Dickinson
Cymabay Therapeutics
Chief Regulatory and Compliance Officer
You may also like
Source: SEC filing on May 15, 2020.